# Rapport Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rapport-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.rapportrx.com
- Total disclosed funding: $250M
- Latest round: Series B (Aug 7, 2023)
- Investors on record: 11

## About

Based in Massachusetts, US, and founded in 2022, Rapport Therapeutics, Inc. perform researches and develops precision medicine for treating neurological disorders. The firm was established through a partnership between Third Rock Ventures and Janssen Neuroscience. The company was founded by David Bredt. As of 2023, the firm is headed by its CEO Abraham N. Ceesay. In March 2023, the firm raised USD 100 million in Series A funding led by investor Third Rock Ventures, with participation from other investors ARCH Venture Partners and Johnson and Johnson Innovation.

The company offers precision medicine approach, as well as precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). Using receptor-associated proteins, or RAPs, the Rapport platform identifies small molecule therapies that function only on genetically and clinically confirmed targets.

The company plan to use the March 2023 funding for the research and development of precision drugs and therapies for the treatment of neurological diseases.

## Funding rounds

- Series B, Aug 7, 2023, $150M — ARCH Venture Partners, Sofinnova Investments, T Rowe Price, Johnson & Johnson Innovation, Third Rock Ventures, Fidelity Investments, Surveyor Capital, Goldman Sachs Asset Management, Cormorant Asset Management, Perceptive Advisors, Logos Capital
- Series A, Mar 7, 2023, $100M — ARCH Venture Partners, Johnson & Johnson Innovation

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Surveyor Capital — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B